Table 1 Key characteristics of the participants age, growth, weight, pubertal development and glucocorticoid (GC) treatment

n = 19

n = 25

n = 6

n = 12

n = 62

Age

9.6 (±3.0)

11.6 (±2.9)

16.6 (±1.4)

8.9 (±5.8)

11.0 (±4.2)

Age at diagnosis

4.3 (±1.8)

3.6 (±1.9)

5.3 (±2.7)

3.8 (±2.3)

4.0 (±2.0)

Age at loss of ambulation

10.5 (±1.8)

n = 3 (15.8%)

10.8 (±2.5)

n = 6 (25.0%)

11.6 (±1.9)

n = 6 (85.7%)

9.6 (±0.9)

n = 5 (41.7%)

10.7 (±1.9) n = 20 (32.3%)

GC initiated

6.1 (±2.3)

5.3 (±1.3)

7.8 (±1.6)

N/A

5.9 (±1.9)

GC duration

3.8 (±3.2)

6.3 (±3.3)

4.6 (±3.0)

N/A

5.2 (±3.4)

GC stopped

N/A

N/A

11.9 (±3.1)

N/A

11.8 (±3.1)

GC dose at time of investigation^a

0.49 (±0.13) mg/kg/d

0.49 (±0.20) mg/kg/d

N/A

N/A

N/A

Height for age perc. (95% CI)

13.0

(4.4, 21.7)

5.2

(0.2, 10.2)

28.0

(2.2, 53.7)

32.2

(14.4, 49.9)

15.5

(10.0, 21.1)

Weight for age perc. (95% CI)

62.2

(46.3, 78.0)

41.8

(27.6, 56.1)

52.1

(8.4, 95.9)

54.3

(34.7, 73.9)

51.6

(42.8, 60.3)

Iso-BMI

21.6 (4.7)

22.4 (5.2)

22.1 (8.6)

18.3 (2.6)

21.2 (5.0)

Tanner

1–2

1–3

2–5

1–5